Skip to main content

Table 2 Optimization by central composite design

From: Comprehensive stability-indicating method development of Avanafil Phosphodiesterase type 5 inhibitor using advanced Quality-by-Design approach

Run A B C D Rs
(1–2)
Rs
(2–3)
Rs
(3–4)
Rs
(4–5)
Rs
(5–6)
Rs
(6–7)
1 60 4.5 1.25 20 3.571 4.200 16.690 1.200 3.770 0.000
2 60 4.5 0.75 20 3.780 4.950 8.160 1.830 4.323 0.110
3 70 3.5 0.5 30 4.890 1.420 8.800 0.000 0.000 0.200
4 50 5.5 1 30 1.810 3.650 14.630 2.770 2.200 1.860
5 50 5.5 1 10 1.620 3.050 8.220 5.710 3.090 2.680
6 60 2.5 0.75 20 0.000 2.110 0.600 11.100 0.200 4.100
7 50 3.5 0.5 10 1.460 3.790 1.430 1.550 3.320 2.260
8 60 4.5 0.75 20 4.770 5.110 17.530 3.250 1.630 4.450
9 70 3.5 1 10 5.120 1.720 27.140 0.800 8.380 0.000
10 70 5.5 1 10 1.320 1.660 10.710 5.160 1.180 25.00
11 70 5.5 1 30 43.160 1.660 2.041 0.560 0.000 0.100
12 60 4.5 0.75 20 4.740 5.100 17.210 3.140 1.420 4.420
13 60 4.5 0.75 0 2.100 4.590 11.600 2.780 1.290 2.600
14 40 4.5 0.75 20 4.180 11.00 4.015 1.900 6.590 1.820
15 60 4.5 0.25 20 5.150 6.240 23.300 1.800 4.600 0.000
16 70 3.5 1 30 14.750 6.640 1.520 7.920 1.011 4.790
17 60 4.5 0.75 20 5.350 6.440 23.500 1.840 4.610 0.500
18 80 4.5 0.75 20 6.140 1.630 2.510 0.000 0.000 0.950
19 50 5.5 0.5 30 1.510 2.320 15.490 3.007 3.389 0.300
20 50 3.5 1 10 1.920 1.220 4.090 1.110 5.950 1.880
21 70 5.5 0.5 10 1.520 11.990 5.380 1.380 16.00 4.310
22 50 3.5 1 30 1.410 3.320 4.160 6.570 2.370 2.001
23 60 4.5 0.75 20 4.670 5.190 17.330 3.140 1.480 4.310
24 50 3.5 0.5 30 1.220 4.420 1.260 8.710 2.920 0.100
25 70 5.5 0.5 30 0.000 5.070 5.410 32.720 2.650 4.000
26 60 4.5 0.75 40 4.760 5.400 20.400 2.650 1.710 0.800
27 50 5.5 0.5 10 1.990 4.000 10.060 7.280 3.740 2.800
28 60 6.5 0.75 20 0.000 22.160 2.600 3.041 2.000 0.100
29 60 4.5 0.75 20 4.760 5.098 17.410 3.150 1.420 4.410
30 70 3.5 0.5 10 0.000 0.000 3.130 2.330 0.000 0.000
  1. A = Mobile phase ratio, B = pH of buffer, C = Flow rate, and D = Temperature of column